|
|
|
| Therapeutic effect of bevacizumab combined with paclitaxel on lung cancer in mice and its effect on S100A4 and MMP-9 in cancer tissue |
| Mao Weibo1, Zhu Yiling1, Yan Liping1, Zhou Jiahui1, Huang Yuan1, Chen Guorong2 |
| 1.Department of Pathology, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China; 2.Department of Pathology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China |
|
| Cite this article: |
|
Mao Weibo,Zhu Yiling,Yan Liping, et al. Therapeutic effect of bevacizumab combined with paclitaxel on lung cancer in mice and its effect on S100A4 and MMP-9 in cancer tissue[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2020, 50(7): 573-577.
|
|
|
Abstract Objective: To investigate the therapeutic effect of bevacizumab combined with paclitaxel on C57BL/6 lung cancer mice and the effect on cancer tissues S100A4 and MMP-9. Methods: Using rat-derived Leweis lung cancer tumor strains to prepare tumor fluid, SBF level healthy C57BL/6 mice were divided into
normal group (uninoculated tumor fluid), model group (inoculated tumor fluid), bevacizumab group (inoculated tumor fluid), paclitaxel group (inoculated tumor fluid), and bevacizumab combined paclitaxel group (inoculated tumor fluid), with 8 cases in each group. The normal group and the model group were intraperitoneally injected with normal saline twice a week, while bevacizumab group with 15 mg/kg bevacizumab twice a week, the paclitaxel group with 10 mg/kg paclitaxel twice a week; The combination group was intraperitoneally injected with 15 mg/kg bevacizumab and 10 mg/kg paclitaxel twice a week. All mice were killed 2 weeks later, and the eyeballs were taken for blood and weighed. The tumor inhibition rate, IL-2, IL-6, TNF-α, VEGF, S100A4 and MMP-9 contents were detected by enzyme linked immunosorbent assay, T lymphocyte subsets by flow cytometry and VEGF levels by Western blot method. Results: After treatment, the tumor weight, the content of IL-2, IL-6 and TNF-α, VEGF, S100A4 and MMP-9 in bevacizumab group, paclitaxel group and combination group was significantly lower than those in model group, the tumor inhibition rate in combination group was higher than those in bevacizumab group and paclitaxel group, while the content of IL-2, IL-6 and TNF-α, VEGF, S100A4 and MMP-9 in bevacizumab group was significantly lower than those in bevacizumab group (P<0.05). The content of CD3+, CD4+, CD8+ and CD4/CD8 in bevacizumab group, paclitaxel group and combination group was significantly different from those in model group (P<0.05). Conclusion: Bevacizumab combined with paclitaxel can inhibit the growth of C57BL/6 lung cancer in mice, improve their immune function, and reduce the level of vascular endothelial growth factor, S100A4 and MMP-9.
|
|
|
| |
|
|
|
|
|
|
